Cellectricon is presenting a poster titled Decision of Acute and Delayed Onset Toxicity Effects of Alignonucleotide-Based Drugs using In Vitro Models at the Cellectricon conference in Montreal.

At Cellectricon, we create new avenues for neuroscience drug discovery. Our mission is to create outstanding value for our Clients through highly customized in vitro neurobiology services delivering scientific excellence, innovation, and quality of the highest of standards. With a broad platform for in vitro neurobiology research, we help you to: • Accelerate your early R&D process and reduce your time-to-decision making • Obtain novel insights into disease biology and identify targets and lead compounds with potential to produce first-in-class medicines • Benefit from truly collaborative services where scientific exchange and open communication are prioritized to ensure project success Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we create complex disease models and assays for functional and morphological screening. We have established service modules in the areas of Neuroinflammation, Peripheral Neuropathies, Neurodegeneration and Neuroplasticity. Through our services, we can accelerate your target and lead discovery programs.

Founded 2001